异位宁对实验性子宫内膜异位症的作用机理研究
|
摘要
目的：
探讨子宫内膜异位症的发病机理和异位宁治疗子宫内膜异位症的作用机制。
方法：
在成功建立大鼠子宫内膜异位症模型的基础上，我们观察了形态学，并分别采用酶联免疫吸附法、免疫组化、原位杂交方法检测了血清IL-2、IL-10水平，局部病灶组织EGF、PDGF、bcl-2、bax蛋白阳性表达及bcl-2mRNA、baxmRNA的阳性表达。
结果：
1、子宫内膜异位大鼠血清IL-2水平较正常组低，而IL-10水平较正常组高。
2、子宫内膜异位大鼠局部病灶组织，bcl-2mRNA及蛋白的阳性表达较正常组高，而baxmRNA及蛋白的阳性表达较正常组低。
3、子宫内膜异位大鼠局部病灶组织EGF和PDGF蛋白的阳性表达较正常组高。
结论：
1、免疫调节失衡与子宫内膜异位症的发生发展有关。
2、细胞凋亡能力降低在子宫内膜异位症的发展中起重要作用。
3、血管生成促进了异位内膜的种植和生长。
4、异位宁能够调整免疫失衡，诱导异位内膜细胞凋亡，抑制异位内膜组织新生血管生成。
Purpose:
To explore the pathogensis of endometriosis and therapeutic mechanism ofYWN.
Method:
On successfully creating EM model of rats, we investigate histomorphology, the level of interleukin-2 (IL-2) and interleukin-10 (IL-10) in serum with ELISA, the positive expressions of EGF, PDGF, bcl-2 and bax protein in the focal tissue with immunohistochemical method, and the positive expressions of bcl-2 mRNA and bax mRNA in the focal tissue with In situ hybridization.
Result:
1. The level of IL-2 in serum was lower in EM group than that in normal group, while the level of 11-10 was higher.
2.The positive expressions of bcl-2 mRNA and protein in the focal tissue were higher in EM group than that in normal group, while the positive expressions of bas mRNA and protein were lower.
3.The positive expressions of EOF and PDGF protein in the focal tissue were higher in EM group than that in normal group.
Conclusion:
1 .The imbalance of immune system may be related to the occurrence and development of EM.
2.The abatement of programmed cell death in ectopic endometrium may play an important role in the development of EM.
3.The growth of new vessels in ectopic endometrium could promote the implantation and growth of ectopic endometrium.
4.YWN could regulate the imbalance of immune system, induce programmed cell death in ectopic endometrium, and inhibit the growth of new vessels in ectopic endometrium.
探讨子宫内膜异位症的发病机理和异位宁治疗子宫内膜异位症的作用机制。
方法：
在成功建立大鼠子宫内膜异位症模型的基础上，我们观察了形态学，并分别采用酶联免疫吸附法、免疫组化、原位杂交方法检测了血清IL-2、IL-10水平，局部病灶组织EGF、PDGF、bcl-2、bax蛋白阳性表达及bcl-2mRNA、baxmRNA的阳性表达。
结果：
1、子宫内膜异位大鼠血清IL-2水平较正常组低，而IL-10水平较正常组高。
2、子宫内膜异位大鼠局部病灶组织，bcl-2mRNA及蛋白的阳性表达较正常组高，而baxmRNA及蛋白的阳性表达较正常组低。
3、子宫内膜异位大鼠局部病灶组织EGF和PDGF蛋白的阳性表达较正常组高。
结论：
1、免疫调节失衡与子宫内膜异位症的发生发展有关。
2、细胞凋亡能力降低在子宫内膜异位症的发展中起重要作用。
3、血管生成促进了异位内膜的种植和生长。
4、异位宁能够调整免疫失衡，诱导异位内膜细胞凋亡，抑制异位内膜组织新生血管生成。
Purpose:
To explore the pathogensis of endometriosis and therapeutic mechanism ofYWN.
Method:
On successfully creating EM model of rats, we investigate histomorphology, the level of interleukin-2 (IL-2) and interleukin-10 (IL-10) in serum with ELISA, the positive expressions of EGF, PDGF, bcl-2 and bax protein in the focal tissue with immunohistochemical method, and the positive expressions of bcl-2 mRNA and bax mRNA in the focal tissue with In situ hybridization.
Result:
1. The level of IL-2 in serum was lower in EM group than that in normal group, while the level of 11-10 was higher.
2.The positive expressions of bcl-2 mRNA and protein in the focal tissue were higher in EM group than that in normal group, while the positive expressions of bas mRNA and protein were lower.
3.The positive expressions of EOF and PDGF protein in the focal tissue were higher in EM group than that in normal group.
Conclusion:
1 .The imbalance of immune system may be related to the occurrence and development of EM.
2.The abatement of programmed cell death in ectopic endometrium may play an important role in the development of EM.
3.The growth of new vessels in ectopic endometrium could promote the implantation and growth of ectopic endometrium.
4.YWN could regulate the imbalance of immune system, induce programmed cell death in ectopic endometrium, and inhibit the growth of new vessels in ectopic endometrium.
引文
[1]《黄帝内经素问》 北京：人民卫生出版社 1963年第1版
[2]《灵枢经》 北京：人民卫生出版社影印本(据明．赵府居敬堂刊本)，1956年第1版
[3]汉．张仲景 《金匮要略方论》 北京：人民卫生出版社 1963年第1版
[4]晋．王叔和 《脉经》 上海：商务印书馆 1940年初版，1954年印刷
[5]隋．巢元方 《诸病源候论》 北京：人民卫生出版社(据清刊《周氏医学丛书》本影印)1956年6月第1版，1982年4月第5次印刷
[6]唐．孙思邈 《备急千金要方》 北京：人民卫生出版社(据江户医学影宋本影印) 1982年9月第1版
[7]宋．陈自明著，明．熊宗立补遗，明．薛己校注(余瀛鳌等点校) 《妇人良方校注补遗》 上海：上海科学技术出版社 1992年2月第1版
[8]元．朱震亨 《丹溪心法》 见：《金元四大家医学全书》本 天津：天津科学技术出版社1994年6月第1版
[9]明．张景岳 《景岳全书》 上海：上海科学技术出版社(据岳峙楼藏版影印) 1959年第1版
[10]明．武之望 《济阴纲目》 上海：上海科技出版社 1958年11月第1版 1959年3月第3次印刷
[11]明．万全 《万氏女科》 见：《万密斋医学全书》本第三函 忠信堂刻本
[12]清．傅山 《傅青主女科》 上海：上海科学技术出版社 1959年3月第1版 1961年9月第3次印刷
[13]清．徐灵胎 《女科指要》 见：《徐灵胎医书三十二种》本 上海：锦文堂书局民国间石印
[14]清．王清任 《医林改错》 北京：人民卫生出版社 1976年
[15]清．阎纯玺 《胎产心法》 北京：人民卫生出版社 1988年12月
[16]陈锦秀 毛美蓉治疗子宫内膜异位症经验 湖北中医杂志 1995：17(4)31
[17]秦淑芳 韩冰教授治疗子宫内膜异位症的临床经验 天津中医 1995：12(6)9
[18]王蕾，等 李春英教授治疗子宫内膜异位症的经验 北京中医 1999；(5)44
[19]周惠芳 补肾化瘀法治疗子宫内膜异位症34例 吉林中医药 1997；(5)18
[20]简永平，等 活血化膜汤治疗子宫内膜异位症38例 福建中医药 1997：28(2)15
[21]金季玲 加味桂枝茯苓丸治疗子宫内膜异位症95例 辽宁中医杂志 1994；21(6)271
[22]戴峻，等 中西医结合治疗子宫内膜异位症79例临床分析 贵阳中医学院学报 1997；19(增刊)28
[23]徐志华，等 痛经散治疗子宫内膜异位症30例 安徽中医学院学报 1988；7(4)20
[24]张志枫，等 化瘀通腑法对子宫内膜异位症痛经的治疗作用及机理探讨 中医杂志 1995；36(1)679
[25]李颖 活血通腑法治疗盆腔子宫内膜异位症89例临床观察 新中医 1996；(3)26
[26]韦丽君 内外合治盆腔子宫内膜异位症 江西中医药 1988：29(3)24
[27]苏颖 张丽蓉治疗子宫内膜异位症经验 天津中医 2000；17(2)2
[28]沈岚 活血化瘀清热法治疗子宫内膜异位症56例 江苏中医 1998；19(3)10
[29]李雅华 三联疗法治疗子宫内膜异位症56例 广西中医药 2000；23(1)30
[30]魏爱平，等 活血益肾法治疗子宫内膜异位不孕症30例 北京中医药大学学报 1995；18(6)44
[31]奚嘉 内异方治疗子宫内膜异位症临床观察 山东中医杂志 2000；19(10)594
[32]朱鸿全 桃仁马鞭汤治疗子宫内膜异位症46例临床观察 新中医 1997；29(6)18
[33]王俊玲，等 罗氏内异方治疗子宫内膜异位症的临床观察 中国中西医结合杂志 1997；17(4)238
[34]马菡，等 手红方治疗子宫内膜异位症30例 湖南中医杂志 1999；15(3)57
[35]席慧 中西医结合治疗子宫内膜异位症性不孕 江苏中医 1998；19(3)14
[36]应瑛 化膜汤治疗子宫内膜异位症 浙江中医学院学报 1998；22(2)23
[37]刘金星，等 化瘀消痰、软坚散结法治疗子宫内膜异位症的临床研究 中国中西医结合杂志 1994；14(6)337
[38]周元荣，等 痰瘀分消法治疗子宫内膜异位症60例临床观察 新中医 1999；31(1)19
[39]吴凡 辨证治疗子宫内膜异位症53例 辽宁中医杂志 1997；24(3)122
[40]常暖，等 妇痛宁治疗子宫内膜异位症临床和实验研究 中医杂志 1997；38(8)488
[41]高月平，等 温肾疏肝、祛痰化瘀法治疗盆腔子宫内膜异位症37例 南京中医药大学学报 1996；12(5)55
[42]蔡辉，等 活血调经方治疗子宫内膜异位症的临床研究 中医药学报 1996；(1)19
[43]田延竹 温补肾阳法治疗子宫内膜异位症21例 陕西中医 1997；18(6)252
[44]侣雪平 自拟内异方治疗子宫内膜异位症50例临床观察 中国中医药科技 1999；6(2)121
[45]霍清萍 补肾化瘀法治疗子宫内膜异位症32例 江苏中医 1998；19(1)
[46]叶素萍 何嘉琳治疗子宫内膜异位症经验 安徽中医临床杂志 1999；11(5)333
[47]胡启梅，等 补阳活血消癥法治疗“内异症”痛经30例 江苏中医 1995；16(1)16
[48]钱静，等 温肾化瘀法治疗子宫内膜异位症的临床研究 南京中医药大学学报 2000；16(5)277
[49]王翠霞，等 中医辨证治疗子宫内膜异位症30例 辽宁中医杂志 1998；25(12)12
[50]胡国珍，等 活血化瘀法治疗子宫内膜异位症48例 上海中医药杂志 1995；(2)38
[51]王兴娟，等 芪蚣汤治疗子宫内膜异位症26例 上海中医药杂志 1995；(9)24
[52]刘秀红 子宫内膜异位症的辨证论治 河南中医 1998；18(6)386
[53]夏融 朱南孙治疗子宫内膜异位症经验 中医文献杂志 1999；(2)30
[54]王志莲，等 子宫内膜异位症的免疫状态与中医辨证分型的关系 中国中医基础医学杂志 1999；5(6)33
[55]李先菊 中药保留灌肠治疗子宫内膜异位症64例 湖南中医杂志 1999；15(4)34
[56]朱良玉 40例子宫内膜异位症临床观察 上海中医药杂志 1994；(1)12
[57]皇甫礼，等 活血化瘀为主治疗子宫内膜异位症42例临床观察 云南中医药杂志 1995；16(5)14
[58]王均友 曹慧娟教授治疗子宫内膜异位症止痛八法 北京中医药大学学报 2001；24(1)55
[59]俞超芹，等 内异Ⅱ号治疗子宫内膜异位症实验研究 中国实验方剂学杂志 1996；2(5)17
[60]裴玉环，等 “内异丸合剂”治疗子宫内膜异位症2000例疗效观察 中国中医基础医学杂志 1999；5(11)49
[61]谢正卿 温经散寒治疗子宫内膜异位症 四川中医 1999；17(9)40
[62]瞿结宗，等 中药配合激光治疗子宫内膜异位症102例疗效分析及实验研究 陕西中医 1995；16(12)529
[63]刘健，等 补肾祛瘀法治疗子宫内膜异位症的临床观察 中国中西医结合杂志 1998；18(3)145
[64]宋雅萍 活血化瘀法治疗子宫内膜异位症28例 陕西中医 1995；16(12)531
[65]于兆安，等 乐脉颗粒治疗子宫内膜异位症的临床观察 中国中医药科技 1996；3(4)39
[66]黄碧珠 消瘾止痛散治疗子宫内膜异位症的临床体会 北京中医 1999；(5)35
[67]葛帮雨 内异煎治疗子宫内膜异位症67例疗效观察 河南中医 1998；18(2)50
[68]翟敏 穿蛭合剂治疗子宫内膜异位症48例临床观察 河北中医 1999；21(2)87
[69]胡兆明 加味阳和汤治疗子宫内膜异位症27例 浙江中医杂志 1997；21(2)208
[70]闵肖岚，等 加味绀珠正气天香散治疗痛经：朱葆初治疗子宫内膜异位症的经验 上海中医药杂志 1996；(9)15
[71]程兰，等 大黄“(庶虫)虫丸治疗子宫内膜异位症的临床观察 广东医学 1999；20(7)565
[72]束兰娣 红藤口服液治疗了宫内膜异位症临床观察 上海中医药杂志 1999；(1)30
[73]司徒仪 莪棱合剂治疗子宫内膜异位症58例临床观察 中医杂志 1995；16(5)297
[74]王俊兰，等 “红棱脂汤”治疗子宫内膜异位症46例 江苏中医 1997；18(5)23
[75]乐杰 妇产科学 北京：人民卫生出版社 2001年6月第5版
[76]Brincat M, Galea R, Buhagiar A Polycystic ovaries and endometriosis:a possible connection. Br J Obstet Gynecol, 1994;101(4)346
[77]Comillie FJ, Oosterlynck D, Lauweryns JM,et al. Deeply infiltrating pelvic endometriosis :histology and clinical significance, Fertil Steril 1990;53(6)937
[78]曹泽毅 中华妇产科学 北京：人民卫生出版社 1999年第1版
[79]Hassan HM. Incidence of endometriosis in diagnostic Laparoscopy. J Reprod Med 1976;16(3)135
[80]Decherney AH, Endometriosis, In: Principles and practice of clinical gynecology. John wiley&sons New York 1983;477-482
[81]宋继谒 病理学 北京：科学出版社 1999年1月第一版
[82]Weed JC, Arguemhoarg PC. Endometriosis Can it produce antoimmune response resulting in inferrtility Clin obstet Gynecol 1980;23(6)885
[83]Venturini P L, Semino A, De Gecco L. The biological basis of medical treatment of endometriosis Gynecol Endocrinol 1995;9:259-266
[84]李大金，等 子宫内膜异位症的免疫功能 中国免疫学杂志 1995；11(增刊)87
[85]Laitl J, Miller I, Bukovsky A. et al. Peritoncal macrophages and their activity in sterile patients with endometriosis. Cesk Gynecol 1989;54(9)667
[86]Vigano P, Vercellini P, Di Blasio AM. et al. Deficient antiendometrium lymphocyte-mediated cytotoxicity in patients with endometriosis. Fertil Steril 1991;56(5)894
[87]Oosterlynck DJ, Coxmillie F J, Waer M, et al. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytogoxicity to autologous endometrium. Fertil Steril 1991;56(1)45
[88]halmc J. Pelvic macrophages in endometriosis In: Perspectives in immunoreproduction. New York: Hemisphere Publishing Corporation 1988; 192-197
[89]Dmowski WP, Gebel HM, Rawlins RG, Immunological aspects of endometriosis. Obstet Gynecol Clin North Am 1989;16(1)93
[90]Suganuma N,Harada M, Fumhashi M et al. Apoptosis in humen endometrial and endometriotic tissues, Horm Res 1997;48(supp13)42
[91]McLaren J, Prentice A, Charnock-Jones DS, et al. Immunolocalization of the apoptosis regulating protein Bcl-2 and Bax in human endometrium and isolated peritoneal fluid macrophages in endometriosis. Human Reprod 1997;12:146-152
[92]Gebel HM, Braun DP, Tambur A et al. Spontaneous apoptosis of endometial tissue is impaired in women with endometriosis. Fertril Steril 1998;69(6):1042
[93] Wilson EA. Surgical therapy for endometriosis. Clin Obstet Gynecol 1988;31(4)857-865
[94] Rock JA. Conservative surgery for endometriosis. In:teoh ES et al (eds) Endometriosis. UK:Parthenon 1987; 19-25
[95] Coutinho EM, et al. Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen antiprogesterone Am J Obstet Gynecol 1986;155:761
[96] Venturini PL. Endocrine.Metabolic and clinical effects of gestrinone in women with endometriosis. Fertil Steril 1989; 52:598
[97] Hornstein MD, et al. A randomized double-blind prospective trial of two doses of gestrinone in the treatment of endometriosis. Fertil Steril 1990;53:237
[98] Fentiman IS, et al. Tamoxifen and benign breast problems. Lancet 1987;Ⅱ: 1070
[99] Haber GM et al. Preliminary report on the use of tamoxifen in the treatment of endometriosis. Am J Obstet Gynecol 1987;156:582
[100] 施律琴，张惜阴 他莫西芬治疗子宫内膜异位症的合理方法 上海医科大学学报 1994；21(增刊)140
[101] Vignali M. Molecular action of GnRH analogues on ectopic endometrial cells. Gynecol Obstet Invest 1998:45(suppl)2-5
[102] Dawood MY. Hormonal therapies for endometriosis:Implications for bone metabolism. Acta Obstet Gynecol Scand 1994;supple159:22
[103] Freundl G, godike K, gnoth CH, et al. Steroidal add back therapy in patients treated with GnRH agonists. Gynecol Obstet Invest 1998;45(suppl)22-30
[104] 刘青云 《中药药理学》 1997年12月第1版 北京：人民卫生出版社
[105] 郑俊华 《生药学》 2000年12月第3版 北京：人民卫生出版社
[106] 中药大辞典 上海科技出版社 1986．6．第一版
[107] Donjacour A A, Cunha GR: Stromal regulation of epithelial function. Cancer Treat Res 1991;53:335,
[108] Valverius EM, Cardiello F, Heldin NE, Blondel B, Merol G; stromal influence on transformation of human mammary epithelial cells overexpressing c-myc and SV 40T. J Cell physiol 1990;145(2):207,
[109] Vemon MW, Wilson EA, Studies on the surgical induction of endometriosis in thd rat [J]. Fertil Steril 1995;44:684-694
[110] ILLera MJ, Juan L, Stewart CL et al. Effect of peritoneal fluid from women with endometriosis on implantation in the mouse model [J]. Fertl Steril, 2000;74:41-48
[111] Ingelmo JM, Ouereda F, Acien P. Intraperitoneal and subcutaneous treatment of experimental
endometriosis with recombinant human interferon-alpha-2b in a murine model[J]. Fertil steril,1999;71:907-911
[112]Schenken RS, Williams RF, Hodgen GD. Experimental endometriosis in monkeys [J]. Ann NY Acad Sci, 1991;622:242-255
[113]Hahn DW. Carraher RP. Foldesy RG Me Guire JL. Development of an animal model for quantitatively evaluating effects of drugs on endometriosis [J]. Fertil Steril 1985;14:110-115
[114]肖纯 大鼠实验性子宫内膜异位症模型复制[J] 中国病理生理杂志 1995；11(3)332
[115]郝光荣 实验动物学[M] 上海：第二军医大学出版社 1999；177-178
[116]肖纯 “复宫宁”对大鼠子宫内膜异位症模型的作用[J] 中国病理生理杂志 1999；15(5)404
[117]陈非综述IL-10—一种细胞因子合成的抑制因子 国外医学免疫学分册 1991；14：57
[118]Rogge L, Dighe AS, Gubler U, et al. Regulation of the IL-12 Osubunit expression in developing Th1 and Th2 cells, J Exp Med 1997;185:825
[119]Pemis A, Gupta S, gollob KJ, et al. Lack of Interferon-Y receptor β chain and the prevention ofinterferon-Y signaling in Th1 cells. Science, 1995;269:245
[120]Trauth N, Shulth LD, Brombacher F, et al. An interleukin -4 independent pathway for CD4~+ T cell IL-4 production is revealed in IL-4 recepter-deficient mice. Proc Natl Acad Sci USA 1997;94:10838
[121]Pfeiffer C, Stein J, Southwood S, et al. Altered Peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995; 181:1569
[122]Milich DR, Schodel F, Hughes JL, et al. The hepatitis B core and e antigens elicit different Th cell subsets: Antigen stucture can affect Th cell phenotype. J Virol 1997;71:2192
[123]Kuchroo VK, Das MP, Brown JA, et al. B7-1and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways :Application to autoimmune disease therapy.cell, 1995;80:707
[124]Del prete G, Carli MD, Almerigogna F, et al. Preferential expression of CD30 by human CD_4+ T cells producing Th2-type cytokines. FASEB J, 1995;9:81
[125]Annunziato F, Manetti R, Tomasevic L, et al. Preferential expression of LAG-3 by CD_4+ T cells producing Th1-type cytokines. FASEB J, 1996;10:767
[126]Hili J A. Immunology and endometriosis. Fertil Steril 1992;58(3):262
[127]张淑芝，等 子宫内膜异位症并不孕患者腹腔液淋巴细胞及其白细胞介素-2的变化中华妇产科杂志 1998：33(1)：17
[128]Hill JA, Ahclerson DJ. Lymphocyte activity in the presence of peritoneal fluid from fertile women and infertile women with and without endometriosis. Am J Obstet Gynecol 1989;161:861-864
[129]furukawa Y, Becker G, Stinn L, et al. Interleukin-10 augments allograft arterial disease: paradoxical effects of IL-10 in vivo. Am J Patnol 1999; 155:1929-1939
[130]Punnonen J, Teisala K, Ranta H, et al.Increased levels of interleukin-6 and interleukin-10 in thd peritoneal fluid of patient with endometriosis. Am J Obstet Gynecol 1996; 174:1522-1526
[131]Llorente L, Zou W, Levy Y, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181:839-844
[132]Dmowski WP, Gebel HM, Braun DP, the role of cell-mediated immunity in pathogenesis of endometriosis. Acta Obstet Gynecol Scand, 1994; 159(suppl):7-14
[133]HSU DH, Moore KW, Spits H. Differential effects of IL-4and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity. Int Immunol 1992;4:563
[134]De Waal-Malefyt R, Yssel H, de Vries J E. Direct effects of IL-10on subsets of human CD_4+T cell clones and resting T cells:specific inhibition of IL-2 production and proliferation. J. Immunol, 1993;150:4754
[135]Wy Uie AH, Kerr JFR, Currie AR, et al. Cell death: the significance of apoptosis .Int Rev cytol 1980;68:251-360
[136]Yang E and Korsmeyer ST. Molecular thanatopsis: disuss on the Bcl-2 family and cell death. Blood 1996;88:386
[137]Cosulich SG, Worrall V, Hedge PT, et al. Regulation of apoptosis by BH3 domains in a cell-free system. Curre Bid 1997;71:913
[138]Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cell with the t (14:18) chromosome translocation. Science.1984;226:1097-1098
[139]Poulsom R, Wong L, Hanby AM, et al. bcl-2 expression in adult and embryonic non-haematopoietic tissues J Pathol 1993;169:431
[140]Watanabe H, Kanzaki H, Narukawa S, et al. bcl-2and Fas expression in eutopic and ectopic human endometrium during the menstrual cycle in relation to endometrial cell apoptosis. Am J Obstet Gynecol 1997;176:360-368
[141]Monaghan PD, Robertson AS, Amos MJ, et al. Ultrastructural localization of bcl-2 protein. J Histochem Cytochem 1992;40:1819-1825
[142]Vaux D, Cory S, Adams JM, et al. bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442
[143]Oltrai ZN, Melliman CL, Korsmeyer S J, et al. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax ,that accelerates propramed cell death. Cell 1993,74:609-619
[144]Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical determination of in vivo distribution of bax,a dominant inhibitor of bcl-2. Am J Pathol 1994;45:1323-1336
[145]Hopwood D, Levison DA. Atrophy and apoptosis in the cyclical human endometrium. J Pathol 1976;119:159-166
[146]Otsuki Y, Misaki O, Sugimoto O, et al. Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycle, Lancet, 1994;344:28-29
[147]Gompel A, Sabourin JC, Martin A, et al. bcl-2 expression in normal endometrium during the menstrual cycle Am J Pathol 1994;144;1195-1202
[148]Jone RK, Searle RF, Bulmer JN. Apoptosis and bcl-2 expression in normal human endometrium, endometrium, endometriosis and adenomyosis. Hum Reprod 1998;13:3496
[149]Otsuki Y, Miaki O, Sugimoto O, et al. Cyclic bcl-2 gene expression in human endometrium during menstrual cycle. Lancet 1994;344:28
[150]Tao XJ, TilIy KI, Maravei DV, et al. Differential expression of members of the bcl-2 gene family in proliferative and sevetory human endometrlum: glandular epithelial cell apoptosis is associated with increase expression of Bax.J clin Endocrinol Metab 1997;82:2738
[151]Dahmoun M, Boman K, Cajander S, et al. Apoptosis, proliferation, and sex hormone receptors in superficial parts of human endometrium at the end of the secretory phase .J Clin Endocrinol Metab 1999;84:1737
[152]黄凤英，林秋华，方小玲 Bcl-2和bax蛋白在正常子宫内膜中的表达 中华妇产科杂志 1999；34：654
[153]Von Rango U, Classen-linke I, Krusche CA, et al. The receptive endometrium is characterized by apoptosis in the glands. Hum Reprod 1998;13;3177
[154]Vaux DL, Strasser A. The molecular biology of apoptosis.Proc Natl Acad Sci USA 1996;93:2239-2244
[155]Hockenbery D, Nunez G, Milliman C, Schreiber KD, Korsmeyer SJ:bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334
[156]Reed JC, Bcl-2 and the regulation of programmed cell death. J Cell Boil 1994; 124:1-6
[157]Oltvai ZN, Miliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog bax that accelerates programmed cell death. Cell, 1993;74(4):609
[158]Korsmeyer S, Shutter J, Veis D, et al. Bcl-2/Bax:a rheostat that regulates an antixidant
pathway and cell death. Semin Caucer Boil 1993;4(6):327
[159]Gaetje R, Kotzian S, Hemnann G, et al. Invasiveness of endometriotic cells in vitro. Lancet 1995;346:1643-1644
[160]Dmowski WP, Gebel H, Braun DP, Decreased apoptosis and sensiticity to macrophage cytolysis of endometrial cell in endometriosis. Hum Reprod Update 1998;4:696
[161]黄凤英，方小玲，林秋华 凋亡调节蛋白bcl-2/bax与子宫内膜异位症 国外医学妇产科分册 1999；26(2)：81
[162]Mahmoud A, Khalifa Md, Ahmed A, et al. Prognostic utility of epidermal growth factor receptor overexpresson in endometrial adenocarinoma. Cancer 1994;73:370-376
[163]Athanassiadou P, Petrakakou E, liossi A, et al. Prognostic significance of P53, Bcl-2 and EGFR in carcinoma of the endometrium. Acta Cytal, 1999;43:1039-1044
[164]Poulsom R, Wong L, Hanby Am, et al. Bcl-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol 1993;169:431
[165]Pinanl M, Milani S, Herbst H, et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrosis [J]. Am J Pathol 1996;148(3):785
[166]Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor [J]. Physiol Rev 1999;79(4):1283-1316
[167]Heldin CH, Ostman A, Ronnstrancl L. Signal transduction Via platelet-derived growth factor receptors [J]. Biochem Biophys Acta, 1998;1378(1):F79-F113
[168]Kanzaki M, Koji Imal 1. Recent advances in growth factor receptor research [J]. Nippon Rinsho, 1998;56(7)1791-1793
[169]Burt AD, Celluar and molecular aspects of hepatic fibrosis [J]. J Pathology, 1993;170(2):105
[170]Wang L, Yamasaki G, Johnso R, et al. Induction of β-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture [J]. J clin Invest, 1994;94(4): 1563
[171]Rao CD, Igaraghi H, chiu IM, et al. Structure and sequence of the human c-sis/platelet-derived growth factor 2(SIS/PDGF2) transcriptional unit. Proc Natl Acad Sci USA,1986,83:2392-2396
[172]Betsholtz C, Johnsson A, Heldin CH, et al. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines. Nature 1986;320:695-699
[173]Friedman SL. Closing in on the signals of hepatic fibrosis[J]. Grasstroenterology 1997;
112(4):1406
[174]Sarkissian M, Lafyatis R. Transforming growth factor-beta and platelet derived growth factor regulation of fibrillar fibronectin matrix formation by synovial fibrololasts [J]. J Rhewmatol 1998;25(4):613-622
[175]Verbeek BS, Vroom TM, Rijksen G. Overexpression of c-sre enhances cell-matrix adhesion and cell migration in PDGF-stimulated NIH3T3 fibroblasts [J]. Exp cell Res, 1999;248(2):531-537
[176]DeMali KA, Balciunaite E, Kazlauskas A. Integrins enhance platelet-derived growth factor (PDGF)-dependent responses by altering the signal relay enzymes that are recruited to the PDGFbeta receptor[J]. J Biol chem. 1999;274(28):19551-19558
[177]Potgyen A J, Lubsen MC, Schoenmakers D J et al. Vascular permeability factor expression influences tumour angiongenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1993;146:147
[178]Koch AE, Harlow G, Haines E et al. Vascular endothelial growth factor. Acytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1995;152:4149
[179]Ravindranatb NL, Little-Ihring HS, Phillips N et al. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 1992,131:254
[180]Smith SK. Angiogenesis Reproductive Endocrinol 1996;15:221
[181]Nisolle M, RouxF, Anaf V, et al. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril 1993;59:681
[182]Oosterlynck D, et al. Angiosgenic activity of peritoneal fluid from women with endometriosis [J] Fertil Steril 1993;59:778
[183]Oosterlynck D, et al. TGF-β activity is increased in peritoneal fluid from women with endometriosis [J] Obstet Gynecol 1994;83:287
[184]Mc:aren-J et al. VEGF concentratriosis[J]. From women with endometriosis Obstet Gynecol 1994;83:287
[185]Ryan IP, et al. IL-8 concentrations are elevated in peritoneal fluid of women with endometriosis [J]. Fertil Steril 1995;63:929
[186]Boland NI & Gosden RG: Effects of epidermal growth factor on the growth and differentiation of cultured mouse ovarian follicles, J Reprod Fertil 1994; 101: 369
[2]《灵枢经》 北京：人民卫生出版社影印本(据明．赵府居敬堂刊本)，1956年第1版
[3]汉．张仲景 《金匮要略方论》 北京：人民卫生出版社 1963年第1版
[4]晋．王叔和 《脉经》 上海：商务印书馆 1940年初版，1954年印刷
[5]隋．巢元方 《诸病源候论》 北京：人民卫生出版社(据清刊《周氏医学丛书》本影印)1956年6月第1版，1982年4月第5次印刷
[6]唐．孙思邈 《备急千金要方》 北京：人民卫生出版社(据江户医学影宋本影印) 1982年9月第1版
[7]宋．陈自明著，明．熊宗立补遗，明．薛己校注(余瀛鳌等点校) 《妇人良方校注补遗》 上海：上海科学技术出版社 1992年2月第1版
[8]元．朱震亨 《丹溪心法》 见：《金元四大家医学全书》本 天津：天津科学技术出版社1994年6月第1版
[9]明．张景岳 《景岳全书》 上海：上海科学技术出版社(据岳峙楼藏版影印) 1959年第1版
[10]明．武之望 《济阴纲目》 上海：上海科技出版社 1958年11月第1版 1959年3月第3次印刷
[11]明．万全 《万氏女科》 见：《万密斋医学全书》本第三函 忠信堂刻本
[12]清．傅山 《傅青主女科》 上海：上海科学技术出版社 1959年3月第1版 1961年9月第3次印刷
[13]清．徐灵胎 《女科指要》 见：《徐灵胎医书三十二种》本 上海：锦文堂书局民国间石印
[14]清．王清任 《医林改错》 北京：人民卫生出版社 1976年
[15]清．阎纯玺 《胎产心法》 北京：人民卫生出版社 1988年12月
[16]陈锦秀 毛美蓉治疗子宫内膜异位症经验 湖北中医杂志 1995：17(4)31
[17]秦淑芳 韩冰教授治疗子宫内膜异位症的临床经验 天津中医 1995：12(6)9
[18]王蕾，等 李春英教授治疗子宫内膜异位症的经验 北京中医 1999；(5)44
[19]周惠芳 补肾化瘀法治疗子宫内膜异位症34例 吉林中医药 1997；(5)18
[20]简永平，等 活血化膜汤治疗子宫内膜异位症38例 福建中医药 1997：28(2)15
[21]金季玲 加味桂枝茯苓丸治疗子宫内膜异位症95例 辽宁中医杂志 1994；21(6)271
[22]戴峻，等 中西医结合治疗子宫内膜异位症79例临床分析 贵阳中医学院学报 1997；19(增刊)28
[23]徐志华，等 痛经散治疗子宫内膜异位症30例 安徽中医学院学报 1988；7(4)20
[24]张志枫，等 化瘀通腑法对子宫内膜异位症痛经的治疗作用及机理探讨 中医杂志 1995；36(1)679
[25]李颖 活血通腑法治疗盆腔子宫内膜异位症89例临床观察 新中医 1996；(3)26
[26]韦丽君 内外合治盆腔子宫内膜异位症 江西中医药 1988：29(3)24
[27]苏颖 张丽蓉治疗子宫内膜异位症经验 天津中医 2000；17(2)2
[28]沈岚 活血化瘀清热法治疗子宫内膜异位症56例 江苏中医 1998；19(3)10
[29]李雅华 三联疗法治疗子宫内膜异位症56例 广西中医药 2000；23(1)30
[30]魏爱平，等 活血益肾法治疗子宫内膜异位不孕症30例 北京中医药大学学报 1995；18(6)44
[31]奚嘉 内异方治疗子宫内膜异位症临床观察 山东中医杂志 2000；19(10)594
[32]朱鸿全 桃仁马鞭汤治疗子宫内膜异位症46例临床观察 新中医 1997；29(6)18
[33]王俊玲，等 罗氏内异方治疗子宫内膜异位症的临床观察 中国中西医结合杂志 1997；17(4)238
[34]马菡，等 手红方治疗子宫内膜异位症30例 湖南中医杂志 1999；15(3)57
[35]席慧 中西医结合治疗子宫内膜异位症性不孕 江苏中医 1998；19(3)14
[36]应瑛 化膜汤治疗子宫内膜异位症 浙江中医学院学报 1998；22(2)23
[37]刘金星，等 化瘀消痰、软坚散结法治疗子宫内膜异位症的临床研究 中国中西医结合杂志 1994；14(6)337
[38]周元荣，等 痰瘀分消法治疗子宫内膜异位症60例临床观察 新中医 1999；31(1)19
[39]吴凡 辨证治疗子宫内膜异位症53例 辽宁中医杂志 1997；24(3)122
[40]常暖，等 妇痛宁治疗子宫内膜异位症临床和实验研究 中医杂志 1997；38(8)488
[41]高月平，等 温肾疏肝、祛痰化瘀法治疗盆腔子宫内膜异位症37例 南京中医药大学学报 1996；12(5)55
[42]蔡辉，等 活血调经方治疗子宫内膜异位症的临床研究 中医药学报 1996；(1)19
[43]田延竹 温补肾阳法治疗子宫内膜异位症21例 陕西中医 1997；18(6)252
[44]侣雪平 自拟内异方治疗子宫内膜异位症50例临床观察 中国中医药科技 1999；6(2)121
[45]霍清萍 补肾化瘀法治疗子宫内膜异位症32例 江苏中医 1998；19(1)
[46]叶素萍 何嘉琳治疗子宫内膜异位症经验 安徽中医临床杂志 1999；11(5)333
[47]胡启梅，等 补阳活血消癥法治疗“内异症”痛经30例 江苏中医 1995；16(1)16
[48]钱静，等 温肾化瘀法治疗子宫内膜异位症的临床研究 南京中医药大学学报 2000；16(5)277
[49]王翠霞，等 中医辨证治疗子宫内膜异位症30例 辽宁中医杂志 1998；25(12)12
[50]胡国珍，等 活血化瘀法治疗子宫内膜异位症48例 上海中医药杂志 1995；(2)38
[51]王兴娟，等 芪蚣汤治疗子宫内膜异位症26例 上海中医药杂志 1995；(9)24
[52]刘秀红 子宫内膜异位症的辨证论治 河南中医 1998；18(6)386
[53]夏融 朱南孙治疗子宫内膜异位症经验 中医文献杂志 1999；(2)30
[54]王志莲，等 子宫内膜异位症的免疫状态与中医辨证分型的关系 中国中医基础医学杂志 1999；5(6)33
[55]李先菊 中药保留灌肠治疗子宫内膜异位症64例 湖南中医杂志 1999；15(4)34
[56]朱良玉 40例子宫内膜异位症临床观察 上海中医药杂志 1994；(1)12
[57]皇甫礼，等 活血化瘀为主治疗子宫内膜异位症42例临床观察 云南中医药杂志 1995；16(5)14
[58]王均友 曹慧娟教授治疗子宫内膜异位症止痛八法 北京中医药大学学报 2001；24(1)55
[59]俞超芹，等 内异Ⅱ号治疗子宫内膜异位症实验研究 中国实验方剂学杂志 1996；2(5)17
[60]裴玉环，等 “内异丸合剂”治疗子宫内膜异位症2000例疗效观察 中国中医基础医学杂志 1999；5(11)49
[61]谢正卿 温经散寒治疗子宫内膜异位症 四川中医 1999；17(9)40
[62]瞿结宗，等 中药配合激光治疗子宫内膜异位症102例疗效分析及实验研究 陕西中医 1995；16(12)529
[63]刘健，等 补肾祛瘀法治疗子宫内膜异位症的临床观察 中国中西医结合杂志 1998；18(3)145
[64]宋雅萍 活血化瘀法治疗子宫内膜异位症28例 陕西中医 1995；16(12)531
[65]于兆安，等 乐脉颗粒治疗子宫内膜异位症的临床观察 中国中医药科技 1996；3(4)39
[66]黄碧珠 消瘾止痛散治疗子宫内膜异位症的临床体会 北京中医 1999；(5)35
[67]葛帮雨 内异煎治疗子宫内膜异位症67例疗效观察 河南中医 1998；18(2)50
[68]翟敏 穿蛭合剂治疗子宫内膜异位症48例临床观察 河北中医 1999；21(2)87
[69]胡兆明 加味阳和汤治疗子宫内膜异位症27例 浙江中医杂志 1997；21(2)208
[70]闵肖岚，等 加味绀珠正气天香散治疗痛经：朱葆初治疗子宫内膜异位症的经验 上海中医药杂志 1996；(9)15
[71]程兰，等 大黄“(庶虫)虫丸治疗子宫内膜异位症的临床观察 广东医学 1999；20(7)565
[72]束兰娣 红藤口服液治疗了宫内膜异位症临床观察 上海中医药杂志 1999；(1)30
[73]司徒仪 莪棱合剂治疗子宫内膜异位症58例临床观察 中医杂志 1995；16(5)297
[74]王俊兰，等 “红棱脂汤”治疗子宫内膜异位症46例 江苏中医 1997；18(5)23
[75]乐杰 妇产科学 北京：人民卫生出版社 2001年6月第5版
[76]Brincat M, Galea R, Buhagiar A Polycystic ovaries and endometriosis:a possible connection. Br J Obstet Gynecol, 1994;101(4)346
[77]Comillie FJ, Oosterlynck D, Lauweryns JM,et al. Deeply infiltrating pelvic endometriosis :histology and clinical significance, Fertil Steril 1990;53(6)937
[78]曹泽毅 中华妇产科学 北京：人民卫生出版社 1999年第1版
[79]Hassan HM. Incidence of endometriosis in diagnostic Laparoscopy. J Reprod Med 1976;16(3)135
[80]Decherney AH, Endometriosis, In: Principles and practice of clinical gynecology. John wiley&sons New York 1983;477-482
[81]宋继谒 病理学 北京：科学出版社 1999年1月第一版
[82]Weed JC, Arguemhoarg PC. Endometriosis Can it produce antoimmune response resulting in inferrtility Clin obstet Gynecol 1980;23(6)885
[83]Venturini P L, Semino A, De Gecco L. The biological basis of medical treatment of endometriosis Gynecol Endocrinol 1995;9:259-266
[84]李大金，等 子宫内膜异位症的免疫功能 中国免疫学杂志 1995；11(增刊)87
[85]Laitl J, Miller I, Bukovsky A. et al. Peritoncal macrophages and their activity in sterile patients with endometriosis. Cesk Gynecol 1989;54(9)667
[86]Vigano P, Vercellini P, Di Blasio AM. et al. Deficient antiendometrium lymphocyte-mediated cytotoxicity in patients with endometriosis. Fertil Steril 1991;56(5)894
[87]Oosterlynck DJ, Coxmillie F J, Waer M, et al. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytogoxicity to autologous endometrium. Fertil Steril 1991;56(1)45
[88]halmc J. Pelvic macrophages in endometriosis In: Perspectives in immunoreproduction. New York: Hemisphere Publishing Corporation 1988; 192-197
[89]Dmowski WP, Gebel HM, Rawlins RG, Immunological aspects of endometriosis. Obstet Gynecol Clin North Am 1989;16(1)93
[90]Suganuma N,Harada M, Fumhashi M et al. Apoptosis in humen endometrial and endometriotic tissues, Horm Res 1997;48(supp13)42
[91]McLaren J, Prentice A, Charnock-Jones DS, et al. Immunolocalization of the apoptosis regulating protein Bcl-2 and Bax in human endometrium and isolated peritoneal fluid macrophages in endometriosis. Human Reprod 1997;12:146-152
[92]Gebel HM, Braun DP, Tambur A et al. Spontaneous apoptosis of endometial tissue is impaired in women with endometriosis. Fertril Steril 1998;69(6):1042
[93] Wilson EA. Surgical therapy for endometriosis. Clin Obstet Gynecol 1988;31(4)857-865
[94] Rock JA. Conservative surgery for endometriosis. In:teoh ES et al (eds) Endometriosis. UK:Parthenon 1987; 19-25
[95] Coutinho EM, et al. Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen antiprogesterone Am J Obstet Gynecol 1986;155:761
[96] Venturini PL. Endocrine.Metabolic and clinical effects of gestrinone in women with endometriosis. Fertil Steril 1989; 52:598
[97] Hornstein MD, et al. A randomized double-blind prospective trial of two doses of gestrinone in the treatment of endometriosis. Fertil Steril 1990;53:237
[98] Fentiman IS, et al. Tamoxifen and benign breast problems. Lancet 1987;Ⅱ: 1070
[99] Haber GM et al. Preliminary report on the use of tamoxifen in the treatment of endometriosis. Am J Obstet Gynecol 1987;156:582
[100] 施律琴，张惜阴 他莫西芬治疗子宫内膜异位症的合理方法 上海医科大学学报 1994；21(增刊)140
[101] Vignali M. Molecular action of GnRH analogues on ectopic endometrial cells. Gynecol Obstet Invest 1998:45(suppl)2-5
[102] Dawood MY. Hormonal therapies for endometriosis:Implications for bone metabolism. Acta Obstet Gynecol Scand 1994;supple159:22
[103] Freundl G, godike K, gnoth CH, et al. Steroidal add back therapy in patients treated with GnRH agonists. Gynecol Obstet Invest 1998;45(suppl)22-30
[104] 刘青云 《中药药理学》 1997年12月第1版 北京：人民卫生出版社
[105] 郑俊华 《生药学》 2000年12月第3版 北京：人民卫生出版社
[106] 中药大辞典 上海科技出版社 1986．6．第一版
[107] Donjacour A A, Cunha GR: Stromal regulation of epithelial function. Cancer Treat Res 1991;53:335,
[108] Valverius EM, Cardiello F, Heldin NE, Blondel B, Merol G; stromal influence on transformation of human mammary epithelial cells overexpressing c-myc and SV 40T. J Cell physiol 1990;145(2):207,
[109] Vemon MW, Wilson EA, Studies on the surgical induction of endometriosis in thd rat [J]. Fertil Steril 1995;44:684-694
[110] ILLera MJ, Juan L, Stewart CL et al. Effect of peritoneal fluid from women with endometriosis on implantation in the mouse model [J]. Fertl Steril, 2000;74:41-48
[111] Ingelmo JM, Ouereda F, Acien P. Intraperitoneal and subcutaneous treatment of experimental
endometriosis with recombinant human interferon-alpha-2b in a murine model[J]. Fertil steril,1999;71:907-911
[112]Schenken RS, Williams RF, Hodgen GD. Experimental endometriosis in monkeys [J]. Ann NY Acad Sci, 1991;622:242-255
[113]Hahn DW. Carraher RP. Foldesy RG Me Guire JL. Development of an animal model for quantitatively evaluating effects of drugs on endometriosis [J]. Fertil Steril 1985;14:110-115
[114]肖纯 大鼠实验性子宫内膜异位症模型复制[J] 中国病理生理杂志 1995；11(3)332
[115]郝光荣 实验动物学[M] 上海：第二军医大学出版社 1999；177-178
[116]肖纯 “复宫宁”对大鼠子宫内膜异位症模型的作用[J] 中国病理生理杂志 1999；15(5)404
[117]陈非综述IL-10—一种细胞因子合成的抑制因子 国外医学免疫学分册 1991；14：57
[118]Rogge L, Dighe AS, Gubler U, et al. Regulation of the IL-12 Osubunit expression in developing Th1 and Th2 cells, J Exp Med 1997;185:825
[119]Pemis A, Gupta S, gollob KJ, et al. Lack of Interferon-Y receptor β chain and the prevention ofinterferon-Y signaling in Th1 cells. Science, 1995;269:245
[120]Trauth N, Shulth LD, Brombacher F, et al. An interleukin -4 independent pathway for CD4~+ T cell IL-4 production is revealed in IL-4 recepter-deficient mice. Proc Natl Acad Sci USA 1997;94:10838
[121]Pfeiffer C, Stein J, Southwood S, et al. Altered Peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995; 181:1569
[122]Milich DR, Schodel F, Hughes JL, et al. The hepatitis B core and e antigens elicit different Th cell subsets: Antigen stucture can affect Th cell phenotype. J Virol 1997;71:2192
[123]Kuchroo VK, Das MP, Brown JA, et al. B7-1and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways :Application to autoimmune disease therapy.cell, 1995;80:707
[124]Del prete G, Carli MD, Almerigogna F, et al. Preferential expression of CD30 by human CD_4+ T cells producing Th2-type cytokines. FASEB J, 1995;9:81
[125]Annunziato F, Manetti R, Tomasevic L, et al. Preferential expression of LAG-3 by CD_4+ T cells producing Th1-type cytokines. FASEB J, 1996;10:767
[126]Hili J A. Immunology and endometriosis. Fertil Steril 1992;58(3):262
[127]张淑芝，等 子宫内膜异位症并不孕患者腹腔液淋巴细胞及其白细胞介素-2的变化中华妇产科杂志 1998：33(1)：17
[128]Hill JA, Ahclerson DJ. Lymphocyte activity in the presence of peritoneal fluid from fertile women and infertile women with and without endometriosis. Am J Obstet Gynecol 1989;161:861-864
[129]furukawa Y, Becker G, Stinn L, et al. Interleukin-10 augments allograft arterial disease: paradoxical effects of IL-10 in vivo. Am J Patnol 1999; 155:1929-1939
[130]Punnonen J, Teisala K, Ranta H, et al.Increased levels of interleukin-6 and interleukin-10 in thd peritoneal fluid of patient with endometriosis. Am J Obstet Gynecol 1996; 174:1522-1526
[131]Llorente L, Zou W, Levy Y, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181:839-844
[132]Dmowski WP, Gebel HM, Braun DP, the role of cell-mediated immunity in pathogenesis of endometriosis. Acta Obstet Gynecol Scand, 1994; 159(suppl):7-14
[133]HSU DH, Moore KW, Spits H. Differential effects of IL-4and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity. Int Immunol 1992;4:563
[134]De Waal-Malefyt R, Yssel H, de Vries J E. Direct effects of IL-10on subsets of human CD_4+T cell clones and resting T cells:specific inhibition of IL-2 production and proliferation. J. Immunol, 1993;150:4754
[135]Wy Uie AH, Kerr JFR, Currie AR, et al. Cell death: the significance of apoptosis .Int Rev cytol 1980;68:251-360
[136]Yang E and Korsmeyer ST. Molecular thanatopsis: disuss on the Bcl-2 family and cell death. Blood 1996;88:386
[137]Cosulich SG, Worrall V, Hedge PT, et al. Regulation of apoptosis by BH3 domains in a cell-free system. Curre Bid 1997;71:913
[138]Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cell with the t (14:18) chromosome translocation. Science.1984;226:1097-1098
[139]Poulsom R, Wong L, Hanby AM, et al. bcl-2 expression in adult and embryonic non-haematopoietic tissues J Pathol 1993;169:431
[140]Watanabe H, Kanzaki H, Narukawa S, et al. bcl-2and Fas expression in eutopic and ectopic human endometrium during the menstrual cycle in relation to endometrial cell apoptosis. Am J Obstet Gynecol 1997;176:360-368
[141]Monaghan PD, Robertson AS, Amos MJ, et al. Ultrastructural localization of bcl-2 protein. J Histochem Cytochem 1992;40:1819-1825
[142]Vaux D, Cory S, Adams JM, et al. bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442
[143]Oltrai ZN, Melliman CL, Korsmeyer S J, et al. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax ,that accelerates propramed cell death. Cell 1993,74:609-619
[144]Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical determination of in vivo distribution of bax,a dominant inhibitor of bcl-2. Am J Pathol 1994;45:1323-1336
[145]Hopwood D, Levison DA. Atrophy and apoptosis in the cyclical human endometrium. J Pathol 1976;119:159-166
[146]Otsuki Y, Misaki O, Sugimoto O, et al. Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycle, Lancet, 1994;344:28-29
[147]Gompel A, Sabourin JC, Martin A, et al. bcl-2 expression in normal endometrium during the menstrual cycle Am J Pathol 1994;144;1195-1202
[148]Jone RK, Searle RF, Bulmer JN. Apoptosis and bcl-2 expression in normal human endometrium, endometrium, endometriosis and adenomyosis. Hum Reprod 1998;13:3496
[149]Otsuki Y, Miaki O, Sugimoto O, et al. Cyclic bcl-2 gene expression in human endometrium during menstrual cycle. Lancet 1994;344:28
[150]Tao XJ, TilIy KI, Maravei DV, et al. Differential expression of members of the bcl-2 gene family in proliferative and sevetory human endometrlum: glandular epithelial cell apoptosis is associated with increase expression of Bax.J clin Endocrinol Metab 1997;82:2738
[151]Dahmoun M, Boman K, Cajander S, et al. Apoptosis, proliferation, and sex hormone receptors in superficial parts of human endometrium at the end of the secretory phase .J Clin Endocrinol Metab 1999;84:1737
[152]黄凤英，林秋华，方小玲 Bcl-2和bax蛋白在正常子宫内膜中的表达 中华妇产科杂志 1999；34：654
[153]Von Rango U, Classen-linke I, Krusche CA, et al. The receptive endometrium is characterized by apoptosis in the glands. Hum Reprod 1998;13;3177
[154]Vaux DL, Strasser A. The molecular biology of apoptosis.Proc Natl Acad Sci USA 1996;93:2239-2244
[155]Hockenbery D, Nunez G, Milliman C, Schreiber KD, Korsmeyer SJ:bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334
[156]Reed JC, Bcl-2 and the regulation of programmed cell death. J Cell Boil 1994; 124:1-6
[157]Oltvai ZN, Miliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog bax that accelerates programmed cell death. Cell, 1993;74(4):609
[158]Korsmeyer S, Shutter J, Veis D, et al. Bcl-2/Bax:a rheostat that regulates an antixidant
pathway and cell death. Semin Caucer Boil 1993;4(6):327
[159]Gaetje R, Kotzian S, Hemnann G, et al. Invasiveness of endometriotic cells in vitro. Lancet 1995;346:1643-1644
[160]Dmowski WP, Gebel H, Braun DP, Decreased apoptosis and sensiticity to macrophage cytolysis of endometrial cell in endometriosis. Hum Reprod Update 1998;4:696
[161]黄凤英，方小玲，林秋华 凋亡调节蛋白bcl-2/bax与子宫内膜异位症 国外医学妇产科分册 1999；26(2)：81
[162]Mahmoud A, Khalifa Md, Ahmed A, et al. Prognostic utility of epidermal growth factor receptor overexpresson in endometrial adenocarinoma. Cancer 1994;73:370-376
[163]Athanassiadou P, Petrakakou E, liossi A, et al. Prognostic significance of P53, Bcl-2 and EGFR in carcinoma of the endometrium. Acta Cytal, 1999;43:1039-1044
[164]Poulsom R, Wong L, Hanby Am, et al. Bcl-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol 1993;169:431
[165]Pinanl M, Milani S, Herbst H, et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrosis [J]. Am J Pathol 1996;148(3):785
[166]Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor [J]. Physiol Rev 1999;79(4):1283-1316
[167]Heldin CH, Ostman A, Ronnstrancl L. Signal transduction Via platelet-derived growth factor receptors [J]. Biochem Biophys Acta, 1998;1378(1):F79-F113
[168]Kanzaki M, Koji Imal 1. Recent advances in growth factor receptor research [J]. Nippon Rinsho, 1998;56(7)1791-1793
[169]Burt AD, Celluar and molecular aspects of hepatic fibrosis [J]. J Pathology, 1993;170(2):105
[170]Wang L, Yamasaki G, Johnso R, et al. Induction of β-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture [J]. J clin Invest, 1994;94(4): 1563
[171]Rao CD, Igaraghi H, chiu IM, et al. Structure and sequence of the human c-sis/platelet-derived growth factor 2(SIS/PDGF2) transcriptional unit. Proc Natl Acad Sci USA,1986,83:2392-2396
[172]Betsholtz C, Johnsson A, Heldin CH, et al. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines. Nature 1986;320:695-699
[173]Friedman SL. Closing in on the signals of hepatic fibrosis[J]. Grasstroenterology 1997;
112(4):1406
[174]Sarkissian M, Lafyatis R. Transforming growth factor-beta and platelet derived growth factor regulation of fibrillar fibronectin matrix formation by synovial fibrololasts [J]. J Rhewmatol 1998;25(4):613-622
[175]Verbeek BS, Vroom TM, Rijksen G. Overexpression of c-sre enhances cell-matrix adhesion and cell migration in PDGF-stimulated NIH3T3 fibroblasts [J]. Exp cell Res, 1999;248(2):531-537
[176]DeMali KA, Balciunaite E, Kazlauskas A. Integrins enhance platelet-derived growth factor (PDGF)-dependent responses by altering the signal relay enzymes that are recruited to the PDGFbeta receptor[J]. J Biol chem. 1999;274(28):19551-19558
[177]Potgyen A J, Lubsen MC, Schoenmakers D J et al. Vascular permeability factor expression influences tumour angiongenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1993;146:147
[178]Koch AE, Harlow G, Haines E et al. Vascular endothelial growth factor. Acytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1995;152:4149
[179]Ravindranatb NL, Little-Ihring HS, Phillips N et al. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 1992,131:254
[180]Smith SK. Angiogenesis Reproductive Endocrinol 1996;15:221
[181]Nisolle M, RouxF, Anaf V, et al. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril 1993;59:681
[182]Oosterlynck D, et al. Angiosgenic activity of peritoneal fluid from women with endometriosis [J] Fertil Steril 1993;59:778
[183]Oosterlynck D, et al. TGF-β activity is increased in peritoneal fluid from women with endometriosis [J] Obstet Gynecol 1994;83:287
[184]Mc:aren-J et al. VEGF concentratriosis[J]. From women with endometriosis Obstet Gynecol 1994;83:287
[185]Ryan IP, et al. IL-8 concentrations are elevated in peritoneal fluid of women with endometriosis [J]. Fertil Steril 1995;63:929
[186]Boland NI & Gosden RG: Effects of epidermal growth factor on the growth and differentiation of cultured mouse ovarian follicles, J Reprod Fertil 1994; 101: 369